Published in PLoS One on November 03, 2014
Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells. Int J Mol Sci (2015) 0.84
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget (2016) 0.75
Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Lett (2017) 0.75
A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A (1995) 32.89
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature (2006) 11.76
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature (2006) 11.18
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76
Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell (2008) 6.62
Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol (1996) 5.17
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol (2007) 5.17
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A (1993) 5.11
Tumor cell senescence in cancer treatment. Cancer Res (2003) 4.15
A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res (1991) 4.07
Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science (2008) 3.77
THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. Cancer Res (1963) 3.74
Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol (2000) 3.49
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol (2004) 3.29
Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations. Science (2011) 3.29
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A (2007) 3.27
DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res (2002) 3.22
Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res (1996) 3.00
Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents (2002) 2.97
A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res (1999) 2.67
Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res (2008) 2.56
Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell (2007) 2.38
Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem (2004) 2.37
Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene (1999) 2.34
Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst (2002) 2.25
Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting. Mol Biol Cell (2005) 2.09
BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res (2009) 1.90
Mammalian cells lack checkpoints for tetraploidy, aberrant centrosome number, and cytokinesis failure. BMC Cell Biol (2005) 1.75
Plx1 is required for chromosomal DNA replication under stressful conditions. EMBO J (2008) 1.73
Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction. Mol Biol Cell (2011) 1.53
Polo-like kinase controls vertebrate spindle elongation and cytokinesis. PLoS One (2007) 1.53
Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol Cancer Ther (2008) 1.53
Human cancer cells commonly acquire DNA damage during mitotic arrest. Cancer Res (2007) 1.47
Sustained mitotic block elicits DNA breaks: one-step alteration of ploidy and chromosome integrity in mammalian cells. Oncogene (2006) 1.42
Polo-like kinase 1 facilitates chromosome alignment during prometaphase through BubR1. J Biol Chem (2007) 1.33
Centromere-localized breaks indicate the generation of DNA damage by the mitotic spindle. Proc Natl Acad Sci U S A (2010) 1.29
Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation. Mol Cell Biol (2009) 1.25
Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery. EMBO Rep (2010) 1.24
Differential control of Eg5-dependent centrosome separation by Plk1 and Cdk1. EMBO J (2011) 1.22
Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem (2008) 1.20
The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence. Cell Cycle (2005) 1.19
Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ (2000) 1.16
MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res (2010) 1.11
Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol (2009) 1.10
SW480, a p53 double-mutant cell line retains proficiency for some p53 functions. J Mol Biol (2005) 1.10
Plk1 regulates the kinesin-13 protein Kif2b to promote faithful chromosome segregation. Mol Biol Cell (2012) 1.10
Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint. Oncogene (2008) 1.09
Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol (2011) 1.03
TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther (2011) 1.02
The polo-like kinase 1 regulates CDC25B-dependent mitosis entry. Biochim Biophys Acta (2009) 0.98
The role of Polo-like kinase 1 in the inhibition of centrosome separation after ionizing radiation. J Biol Chem (2005) 0.94
Continuous polo-like kinase 1 activity regulates diffusion to maintain centrosome self-organization during mitosis. Proc Natl Acad Sci U S A (2011) 0.92
Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway. Cell Cycle (2010) 0.88
Downregulation of Polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway. J Gerontol A Biol Sci Med Sci (2013) 0.85
Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. Cancer Res (2007) 0.84
Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells. World J Gastroenterol (2006) 0.83
Human cells enter mitosis with damaged DNA after treatment with pharmacological concentrations of genotoxic agents. Biochem J (2012) 0.81
Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905). J Med Chem (2011) 0.80
MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma. Mol Cancer Ther (2012) 0.80